Logo image of CSCI

COSCIENS BIOPHARMA INC (CSCI) Stock Fundamental Analysis

NASDAQ:CSCI - Nasdaq - CA22112H1010 - Common Stock - Currency: USD

2.89  +0.17 (+6.25%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CSCI. CSCI was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of CSCI have multiple concerns. CSCI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CSCI has reported negative net income.
CSCI had a negative operating cash flow in the past year.
CSCI had negative earnings in each of the past 5 years.
CSCI had a negative operating cash flow in each of the past 5 years.
CSCI Yearly Net Income VS EBIT VS OCF VS FCFCSCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -32.47%, CSCI is in the better half of the industry, outperforming 64.17% of the companies in the same industry.
CSCI has a Return On Equity (-71.02%) which is in line with its industry peers.
Industry RankSector Rank
ROA -32.47%
ROE -71.02%
ROIC N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSCI Yearly ROA, ROE, ROICCSCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400

1.3 Margins

CSCI has a better Gross Margin (43.00%) than 77.01% of its industry peers.
In the last couple of years the Gross Margin of CSCI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CSCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
CSCI Yearly Profit, Operating, Gross MarginsCSCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CSCI has been reduced compared to 1 year ago.
CSCI has more shares outstanding than it did 5 years ago.
CSCI has a worse debt/assets ratio than last year.
CSCI Yearly Shares OutstandingCSCI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
CSCI Yearly Total Debt VS Total AssetsCSCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.48, we must say that CSCI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.48, CSCI is in the better half of the industry, outperforming 62.03% of the companies in the same industry.
CSCI has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
CSCI has a Debt to Equity ratio of 0.06. This is in the lower half of the industry: CSCI underperforms 64.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -0.48
ROIC/WACCN/A
WACC8.37%
CSCI Yearly LT Debt VS Equity VS FCFCSCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.46 indicates that CSCI has no problem at all paying its short term obligations.
CSCI has a Current ratio of 3.46. This is comparable to the rest of the industry: CSCI outperforms 40.82% of its industry peers.
CSCI has a Quick Ratio of 3.05. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CSCI (3.05) is worse than 62.75% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.05
CSCI Yearly Current Assets VS Current LiabilitesCSCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CSCI have decreased strongly by -274.15% in the last year.
The Revenue has decreased by -7.05% in the past year.
Measured over the past years, CSCI shows a very negative growth in Revenue. The Revenue has been decreasing by -30.07% on average per year.
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.95%
Revenue 1Y (TTM)-7.05%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCI Yearly Revenue VS EstimatesCSCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CSCI Yearly EPS VS EstimatesCSCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CSCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CSCI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCI Price Earnings VS Forward Price EarningsCSCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSCI Per share dataCSCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CSCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COSCIENS BIOPHARMA INC

NASDAQ:CSCI (2/24/2025, 10:32:37 AM)

2.89

+0.17 (+6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners7.38%
Inst Owner Change-54.36%
Ins Owners1.24%
Ins Owner ChangeN/A
Market Cap10.92M
Analysts82.86
Price TargetN/A
Short Float %0.06%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)87.52%
Min Revenue beat(2)66.76%
Max Revenue beat(2)108.29%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.71
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-11
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-4.71
FCFYN/A
OCF(TTM)-4.48
OCFYN/A
SpS1.69
BVpS5.29
TBVpS4.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.47%
ROE -71.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43%
FCFM N/A
ROA(3y)-31.91%
ROA(5y)-27.9%
ROE(3y)-56.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y39.35%
GM growth 5Y0.62%
F-Score1
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.66%
Cap/Sales 13.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.05
Altman-Z -0.48
F-Score1
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)148.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.23%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-274.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-117.95%
EPS Next Y68.75%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.05%
Revenue growth 3Y6.73%
Revenue growth 5Y-30.07%
Sales Q2Q%N/A
Revenue Next Year-2.27%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.76%
OCF growth 3YN/A
OCF growth 5YN/A